Literature DB >> 19103248

Lack of chronic toxicity or carcinogenicity of dietary N-acetylglucosamine in F344 rats.

Miwa Takahashi1, Kaoru Inoue, Midori Yoshida, Tomomi Morikawa, Makoto Shibutani, Akiyoshi Nishikawa.   

Abstract

Chronic toxicity and carcinogenicity of N-acetylglucosamine (GlcNAc) were examined in male and female F344 rats. GlcNAc was given in the diet at levels of 0%, 1.25%, 2.5% or 5% to groups of 10 rats of each sex for 52 weeks in the chronic toxicity study and 0%, 2.5% or 5% to groups of 50 rats of each sex for 104 weeks in the carcinogenicity study. GlcNAc exerted no toxic effects with regard to clinical signs, mortality, hematology, serum biochemistry and histopathological assessment. Slight suppression of body weight gain was observed at more than 2.5%, but this appeared to be due to slight reduction of caloric intake with the high concentration of test compound, rather than any toxicity. Thus, it was concluded that GlcNAc has neither toxic nor carcinogenic effects in F344 rats, the no observed adverse effect levels (NOAEL) estimated from the chronic toxicity study being 5% in both sexes, equivalent to 2323 and 2545 mg/kg/day in males and females, respectively.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19103248     DOI: 10.1016/j.fct.2008.12.002

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   6.023


  9 in total

1.  Glycolytic inhibition: an effective strategy for developing calorie restriction mimetics.

Authors:  Donald K Ingram; George S Roth
Journal:  Geroscience       Date:  2020-11-12       Impact factor: 7.713

2.  N-Acetylglucosamine drives myelination by triggering oligodendrocyte precursor cell differentiation.

Authors:  Michael Sy; Alexander U Brandt; Sung-Uk Lee; Barbara L Newton; Judy Pawling; Autreen Golzar; Anas A Rahman; Zhaoxia Yu; Graham Cooper; Michael Scheel; Friedemann Paul; James W Dennis; Michael Demetriou
Journal:  J Biol Chem       Date:  2020-09-25       Impact factor: 5.157

3.  N-acetylglucosamine inhibits T-helper 1 (Th1)/T-helper 17 (Th17) cell responses and treats experimental autoimmune encephalomyelitis.

Authors:  Ani Grigorian; Lindsey Araujo; Nandita N Naidu; Dylan J Place; Biswa Choudhury; Michael Demetriou
Journal:  J Biol Chem       Date:  2011-09-29       Impact factor: 5.157

4.  Effect of N-acetylglucosamine administration on cartilage metabolism and safety in healthy subjects without symptoms of arthritis: A case report.

Authors:  Daiki Kubomura; Tomoya Ueno; Masanori Yamada; Akihito Tomonaga; Isao Nagaoka
Journal:  Exp Ther Med       Date:  2017-02-21       Impact factor: 2.447

5.  Hexosamine pathway activation improves memory but does not extend lifespan in mice.

Authors:  Kira Allmeroth; Matías D Hartman; Martin Purrio; Andrea Mesaros; Martin S Denzel
Journal:  Aging Cell       Date:  2022-09-19       Impact factor: 11.005

6.  Galectin-3 and N-acetylglucosamine promote myogenesis and improve skeletal muscle function in the mdx model of Duchenne muscular dystrophy.

Authors:  Ann Rancourt; Sébastien S Dufresne; Guillaume St-Pierre; Julie-Christine Lévesque; Haruka Nakamura; Yodai Kikuchi; Masahiko S Satoh; Jérôme Frenette; Sachiko Sato
Journal:  FASEB J       Date:  2018-06-12       Impact factor: 5.191

7.  Oral Supplementation of Glucosamine Fails to Alleviate Acute Kidney Injury in Renal Ischemia-Reperfusion Damage.

Authors:  Marc Johnsen; Martin Richard Späth; Martin S Denzel; Heike Göbel; Torsten Kubacki; Karla Johanna Ruth Hoyer; Yvonne Hinze; Thomas Benzing; Bernhard Schermer; Adam Antebi; Volker Burst; Roman-Ulrich Müller
Journal:  PLoS One       Date:  2016-08-24       Impact factor: 3.240

8.  N-acetylglucosamine drives myelination by triggering oligodendrocyte precursor cell differentiation.

Authors:  Michael Sy; Alexander U Brandt; Sung-Uk Lee; Barbara L Newton; Judy Pawling; Autreen Golzar; Anas M A Rahman; Zhaoxia Yu; Graham Cooper; Michael Scheel; Friedemann Paul; James W Dennis; Michael Demetriou
Journal:  J Biol Chem       Date:  2020-12-18       Impact factor: 5.157

9.  Metabolic Reprogramming by Hexosamine Biosynthetic and Golgi N-Glycan Branching Pathways.

Authors:  Michael C Ryczko; Judy Pawling; Rui Chen; Anas M Abdel Rahman; Kevin Yau; Julia K Copeland; Cunjie Zhang; Anu Surendra; David S Guttman; Daniel Figeys; James W Dennis
Journal:  Sci Rep       Date:  2016-03-14       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.